ID: ALA221615

Max Phase: Preclinical

Molecular Formula: C17H22N8O2

Molecular Weight: 370.42

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1nc(N2CCN3[C@@H](CO)CCC[C@H]3C2)nc2nc(-c3ccco3)nn12

Standard InChI:  InChI=1S/C17H22N8O2/c18-15-20-16(21-17-19-14(22-25(15)17)13-5-2-8-27-13)23-6-7-24-11(9-23)3-1-4-12(24)10-26/h2,5,8,11-12,26H,1,3-4,6-7,9-10H2,(H2,18,19,20,21,22)/t11-,12+/m0/s1

Standard InChI Key:  NVJCHFPWEHYAGF-NWDGAFQWSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 370.42

Molecular Weight (Monoisotopic): 370.1866

AlogP: 0.40

#Rotatable Bonds: 3

Polar Surface Area: 121.84

Molecular Species: NEUTRAL

HBA: 10

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 7.69

CX LogP: 1.90

CX LogD: 1.43

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.67

Np Likeness Score: -1.48

References

1. Peng H, Kumaravel G, Yao G, Sha L, Wang J, Van Vlijmen H, Bohnert T, Huang C, Vu CB, Ensinger CL, Chang H, Engber TM, Whalley ET, Petter RC..  (2004)  Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.,  47  (25): [PMID:15566292] [10.1021/jm0494321]

Source

Source(1):

• Scientific Literature